

Haematologica  
HAEMATOL/2017/171249  
Version 3

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study

Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, and H. Jean Khoury

Disclosures: CG-P has received research funding from Pfizer and has served as an advisor for Pfizer and Bristol-Myers Squibb. JEC has received research support from Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva and is a consultant for Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. JHL has received research funding and consultant or other fees from Bristol-Myers Squibb, Novartis, Teva, Pfizer, and Ariad and lecture fees from Bristol-Myers Squibb and Novartis. HMK has received research funding from Pfizer. D-WK has received research funding from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer; served as a consultant/advisor for Bristol-Myers Squibb, Novartis, and Pfizer; and participated on the speakers bureau for and received honoraria from Bristol-Myers Squibb and Novartis. PS has served as an advisor for and received honoraria from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. THB has participated in advisory boards and satellite symposia for Ariad, Bristol-Myers Squibb, Novartis, and Pfizer; he has also received research funding from Novartis and Pfizer and holds a patent on the combination of imatinib with hypusination inhibitors. HJK has received research funding from and attended compensated advisory boards for Bristol-Myers Squibb, Novartis, Teva, Pfizer, and Ariad. RC, NB-B, KN, EL, and LD are employees of and own stock in Pfizer. MS was an employee of Pfizer when the manuscript was initiated.

Contributions: Study creation/design was performed by CG-P, JC, MS, and HJK. Data collection was performed by CG-P, JC, JHL, HMK, D-WK, PS, THB, and HJK. Analysis and/or interpretation of the data was performed by CG-P, JC, JHL, HMK, D-WK, PS, MS, THB, HJK, RC, NB-B, EL, KN, and LD. Study materials and/or enrolled patients were provided by CG-P, JC, JHL, HMK, D-WK, PS, MS, THB, and HJK. EL performed statistical analyses. All authors reviewed, edited and approved the manuscript.